GOSS news

Gossamer Bio appointed longtime biopharma investor Greg Ciongoli to its board to support the advancement of its pipeline, including the PAH therapy seralutinib.

On July 14, 2026, stockholders approved an amendment to amend the capitalization of the Corporation by authorizing shares exchange for a 1-for-80 reverse stock split. Upon filing, shares will automatically reclassify and become effective on September 10, 2026, subject to Nasdaq listing.

The company amended its bylaws effective September 3, 2026, to increase control over shareholder nominations. This corporate governance change may influence upcoming board elections and shareholder activism.

Gossamer and Chiesi agreed to terminate their collaboration and license agreement, returning rights to Chiesi to pursue other development efforts, settling with post-termination payments.

Gossamer Bio filed an amendment to its charter to increase authorized shares. The company intends to maintain flexibility for potential future equity offerings.

Gossamer Bio announced the initial conversion rate for its 2030 notes and warrant exercise price. These calculations impact future potential dilution for investors and debt holders.

Gossamer Bio announced final results of its exchange offer for 5.00% Convertible Senior Notes due 2027, with $181.052 million in principal amount tendered by the extended early tender date. The company exchanged these notes for new 7.50% Convertible Senior Secured First Lien Notes due 2030, common s…

Gossamer Bio extended the early tender deadline for its exchange offer of 5.00% convertible notes due 2027 for new 7.50% convertible notes, equity securities, and warrants. As of June 1, $181.052 million of the existing notes had been tendered, approaching the 98% minimum threshold required for the …